Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Valeo Pharma Inc VPHIF

Valeo Pharma Inc. is a Canadian pharmaceutical company. The Company acquires, or in-licenses branded pharmaceuticals and hospital specialty products for sale in Canada. The Company is engaged in the commercialization of prescription products in Canada with a focus on respiratory/allergy, ophthalmology and hospital specialty products. Its respiratory/allergy products include Enerzair Breezhaler, Atectura Breezhaler and Allerject. The ophthalmology products include Xiidra and Simbrinza. Its specialty products include Redesca, Onstryv, M-Eslon, Yondelis and Ametop Gel 4%. The Company's wholly owned subsidiary is VPI Pharmaceuticals Inc.


GREY:VPHIF - Post by User

Comment by eric40on Aug 18, 2020 8:37pm
183 Views
Post# 31425960

RE:VPH CEO

RE:VPH CEOTotally agree with you. Valeo is cheap right now considering the nature of the business (No R&D risk), the growing pipeline, an experience team that owns 75% of the cie (because they put their money on the table, not because they got free warrants), many new drugs coming to market in Q3-Q4 2020. Also huge revenu grow in the next 12 months, probably 3 to 5X with generic heparin that will start to sell in the next few weeks. The team is working non stop to search for new drugs already approved and sold in USA and Europe for years (no risk). Also, very important to notice that 4 canadian province including BC are now obligated by law to buy generic drug when available, meaning Valeo generic Heparin sell will ramp up very fast there and with covid19, government dept skyrocketed, so I would not be surprised that all the other provinces mainly Quebec and Ontario will pass a law for generic product to be bought first. For Heparin only, it is 200 million market in Canada and Valeo is the only ''generic Heparin'' available in Canada, so a lot of potential there. And as you say, it is without counting the benefic side of heparin for Covid19 that could help boost the sell further more. YES, Valo is still under the radar and very cheap considering the forecast increase revenu for the next 12 months and further and all the rest. 

I also suggest you another MULTIPLE X upside cie (IMHO): Ortho regenerative technologie, C.ORTH  
https://www.orthorti.com/

This is an R&D cie, so yes it is more risky, but if you take 10 minutes to read what they are working on on their website, you will understand that it is not so risky and the upside potential in the next 24 months is a possible 20X or more.

I believe they will start their phase 1 clinical trial for rotary cuff repair next quarter.
<< Previous
Bullboard Posts
Next >>